Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma

Bortezomib-induced peripheral neuropathy (BIPN) often is difficult to manage or reverse once it occurs. Treatment usually involves dose-reduction, interruption, or cessation of therapy, as no other interventions have been proven effective. Oncology nurses must be vigilant and recognize BIPN early to prevent patients from experiencing symptoms and complications that may interfere with their quality of life.